Skip to content
Screener

LivaNova LIVN Financing Cash Flow

Financing Cash Flow at other companies

Abbott logo
AbbottABT
$17.31B+942%
Haemonetics logo
HaemoneticsHAE
-$51.53M-2,010%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
-$166K-101%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
-$7.48M+91.5%
Medtronic logo
MedtronicMDT
-$888M+33.9%
ITG
Integer HoldingsITGR
$3.83M-97.5%

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Repayment of long-term debt obligations(95,938)(210,250)
Payment of contingent consideration(50,429)
Other, net(4,326)(3,153)
Net cash used in financing activities(150,693)(213,403)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash(3,547)16,195
Net decrease in cash, cash equivalents, and restricted cash(118,933)(129,918)
Cash, cash equivalents, and restricted cash at beginning of period635,552723,556
Cash and cash equivalents at end of period$516,619$593,638

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's financing cash flow?
LivaNova (LIVN) reported financing cash flow of -$56.45M in Q2 2026.
How has LivaNova's financing cash flow changed year-over-year?
LivaNova's financing cash flow increased by 73.0% year-over-year, from -$208.98M to -$56.45M.
What is the long-term trend for LivaNova's financing cash flow?
Over 2 years (2021 to 2025), LivaNova's financing cash flow has grown at a 25.5% compound annual growth rate (CAGR), from -$181.48M to -$285.66M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about LivaNova's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude